AU2016226699B2 - Ophthalmic compositions and methods of use therefor - Google Patents

Ophthalmic compositions and methods of use therefor Download PDF

Info

Publication number
AU2016226699B2
AU2016226699B2 AU2016226699A AU2016226699A AU2016226699B2 AU 2016226699 B2 AU2016226699 B2 AU 2016226699B2 AU 2016226699 A AU2016226699 A AU 2016226699A AU 2016226699 A AU2016226699 A AU 2016226699A AU 2016226699 B2 AU2016226699 B2 AU 2016226699B2
Authority
AU
Australia
Prior art keywords
composition
corneal
tgfp3
dexamethasone
eye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016226699A
Other languages
English (en)
Other versions
AU2016226699A1 (en
Inventor
Colin Green
Carol Ann GREENE
Trevor Sherwin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Theianova Ltd
Original Assignee
Theianova Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theianova Ltd filed Critical Theianova Ltd
Publication of AU2016226699A1 publication Critical patent/AU2016226699A1/en
Application granted granted Critical
Publication of AU2016226699B2 publication Critical patent/AU2016226699B2/en
Assigned to TheiaNova Limited reassignment TheiaNova Limited Request for Assignment Assignors: AUCKLAND UNISERVICES LIMITED
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Peptides Or Proteins (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Physiology (AREA)
  • Botany (AREA)
  • Developmental Biology & Embryology (AREA)
  • Environmental Sciences (AREA)
  • Eyeglasses (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2016226699A 2015-03-05 2016-03-04 Ophthalmic compositions and methods of use therefor Active AU2016226699B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ705727 2015-03-05
NZ70572715 2015-03-05
PCT/NZ2016/050033 WO2016140581A1 (en) 2015-03-05 2016-03-04 Ophthalmic compositions and methods of use therefor

Publications (2)

Publication Number Publication Date
AU2016226699A1 AU2016226699A1 (en) 2017-10-26
AU2016226699B2 true AU2016226699B2 (en) 2020-10-22

Family

ID=56848288

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016226699A Active AU2016226699B2 (en) 2015-03-05 2016-03-04 Ophthalmic compositions and methods of use therefor

Country Status (11)

Country Link
US (2) US10842850B2 (https=)
EP (1) EP3265096B9 (https=)
JP (4) JP2018513117A (https=)
KR (1) KR102450674B1 (https=)
CN (1) CN107530360B (https=)
AU (1) AU2016226699B2 (https=)
ES (1) ES2952700T3 (https=)
MY (1) MY186271A (https=)
SG (1) SG11201708114SA (https=)
TW (1) TWI747816B (https=)
WO (1) WO2016140581A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9622911B2 (en) 2010-09-30 2017-04-18 Cxl Ophthalmics, Llc Ophthalmic treatment device, system, and method of use
EP2830627B1 (en) 2012-03-29 2024-05-01 Epion Therapeutics, Inc. Ocular treatment solutions, delivery devices and delivery augmentation methods
ES2986057T3 (es) 2012-03-29 2024-11-08 Epion Therapeutics Inc Composiciones y métodos para tratar o prevenir enfermedades asociadas al estrés oxidativo
TWI747816B (zh) 2015-03-05 2021-12-01 紐西蘭商奧克蘭聯合服務有限公司 眼用組合物用於製備藥物的用途
KR102706856B1 (ko) 2015-07-21 2024-09-19 아베드로 인코퍼레이티드 광증감제로 눈을 치료하기 위한 시스템 및 방법
CN110092816B (zh) * 2018-01-29 2023-08-01 上海市第一人民医院 预防和治疗纤维化的小分子多肽及其应用
US20210060017A1 (en) * 2018-02-27 2021-03-04 Shilpa Medicare Ltd Methotrexate ophthalmic solution
CN108728418A (zh) * 2018-06-19 2018-11-02 新乡医学院 一种鸡胚中枢神经系统单个神经元动态研究模型的制备方法及应用
WO2020092897A1 (en) * 2018-11-02 2020-05-07 Senseonics, Incorporated Drug eluting matrix on analyte indicator
GB201820021D0 (en) * 2018-12-07 2019-01-23 Univ Birmingham Ocular hydrogel compositions
JP2022125941A (ja) * 2021-02-17 2022-08-29 株式会社ティ・エム・ディ コンタクトレンズ
JP2025529178A (ja) 2022-09-01 2025-09-04 オプティファイ・セラピューティクス・アクティエンゲゼルシャフト 眼科用組成物
EP4687950A1 (en) * 2023-03-30 2026-02-11 Cetel Scientific LLC Amniotic and chorionic collagen for ocular surface healing

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5124392A (en) * 1988-10-03 1992-06-23 Alcon Laboratories, Inc. Pharmaceutical compositions and methods of treatment to prevent and treat corneal scar formation produced by laser irradiation
US5411940A (en) * 1993-09-29 1995-05-02 Alcon Laboratories, Inc. Use of TGF-β3 to reduce the formation of scar tissue in response to corneal trauma

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3786812A (en) * 1972-03-10 1974-01-22 C Neefe Contact lens for olar drug delivery
US4177268A (en) 1973-05-30 1979-12-04 Jouveinal S.A. Method of alleviating inflammation by administration of dexamethasone derivatives
AU660635B2 (en) * 1990-11-16 1995-07-06 Celtrix Pharmaceuticals, Inc. A beta-type transforming growth factor
CN1770976A (zh) 2003-02-13 2006-05-10 人类起源公司 利用脐带血治疗患有疾病、紊乱或状况的个体的用途
MXPA03011987A (es) 2003-12-19 2005-06-23 Osio Sancho Alberto Metodo para el tratamiento de la presbicia induciendo cambios en el poder y fisiologia corneal.
WO2007099337A1 (en) 2006-03-01 2007-09-07 Cartela R&D Ab Expansion and differentiation of mesenchymal stem cells
GB0604938D0 (en) 2006-03-11 2006-04-19 Renovo Ltd Proteins, nucleic acids and medicaments
US7767217B2 (en) 2006-03-14 2010-08-03 Foresight Biotherapeutics Ophthalmic compositions comprising povidone-iodine
US8110655B2 (en) 2006-11-13 2012-02-07 Auxagen, Inc. Method to promote hair growth and/or delay or treat hair loss by administering a TGF-β antagonist or inhibitor
AU2007319811A1 (en) 2006-11-15 2008-05-22 Coda Therapeutics, Inc. Improved methods and compositions for wound healing
JP2011505409A (ja) 2007-12-04 2011-02-24 ノバガリ ファーマ エスエー パルミチン酸デキサメタゾンのようなコルチコステロイドプロドラッグを含有する眼障害の治療用の組成物
US7795316B1 (en) 2007-12-19 2010-09-14 Alcon Research, Ltd. Topical ophthalmic compositions containing tobramycin and dexamethasone
EP2249921B1 (en) 2008-02-25 2020-06-17 Eyegate Pharmaceuticals, Inc. Enhanced delivery of dexamethasone phosphate to ocular tissues through iontophoresis
EP2370054B1 (en) * 2008-12-11 2015-10-07 Massachusetts Institute of Technology Contact lens drug delivery device
US10201548B2 (en) 2009-03-06 2019-02-12 Sun Pharma Global Fze Methods for treating ocular inflammatory diseases
WO2012088044A2 (en) 2010-12-20 2012-06-28 James Mcmillan Compositions and methods for improving ocular surface health, corneal clarity, optical function and maintaining visual acuity
US20130165419A1 (en) * 2011-12-21 2013-06-27 Insite Vision Incorporated Combination anti-inflammatory ophthalmic compositions
KR101518370B1 (ko) 2013-06-25 2015-05-07 가톨릭대학교 산학협력단 Il-10 생성 조절 t세포로의 분화 유도용 조성물
CN104548210A (zh) 2014-12-13 2015-04-29 浙江大学 含地塞米松转化生长因子的可控缓释plga微球及制备
TWI747816B (zh) 2015-03-05 2021-12-01 紐西蘭商奧克蘭聯合服務有限公司 眼用組合物用於製備藥物的用途
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5124392A (en) * 1988-10-03 1992-06-23 Alcon Laboratories, Inc. Pharmaceutical compositions and methods of treatment to prevent and treat corneal scar formation produced by laser irradiation
US5411940A (en) * 1993-09-29 1995-05-02 Alcon Laboratories, Inc. Use of TGF-β3 to reduce the formation of scar tissue in response to corneal trauma

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GREENE C. et al., INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2013, vol. 54, no. 13, page 5250 *
NA K. et al., JOURNAL OF BIOMEDICAL MATERIALS RESEARCH. PART A, 2007, vol. 83A, no. 3, pages 779 - 786, *
WU J. et al., TISSUE ENGINEERING PART A, 2013, vol. 19, no. 17-18, pages 2063 2075 *

Also Published As

Publication number Publication date
US11938168B2 (en) 2024-03-26
JP2018513117A (ja) 2018-05-24
NZ735959A (en) 2021-10-29
CN107530360A (zh) 2018-01-02
US20220047676A1 (en) 2022-02-17
WO2016140581A1 (en) 2016-09-09
MY186271A (en) 2021-07-01
KR20170132197A (ko) 2017-12-01
EP3265096B1 (en) 2023-06-07
JP7641650B2 (ja) 2025-03-07
TWI747816B (zh) 2021-12-01
TW201639592A (zh) 2016-11-16
US10842850B2 (en) 2020-11-24
KR102450674B1 (ko) 2022-10-04
JP2025032318A (ja) 2025-03-11
US20180050088A1 (en) 2018-02-22
ES2952700T3 (es) 2023-11-03
JP2023066425A (ja) 2023-05-15
EP3265096C0 (en) 2023-06-07
JP2021091688A (ja) 2021-06-17
AU2016226699A1 (en) 2017-10-26
EP3265096A1 (en) 2018-01-10
CN107530360B (zh) 2021-09-17
EP3265096A4 (en) 2018-10-24
SG11201708114SA (en) 2017-11-29
EP3265096B9 (en) 2023-10-04

Similar Documents

Publication Publication Date Title
US11938168B2 (en) Ophthalmic compositions and methods of use therefor
Wirostko et al. Novel therapy to treat corneal epithelial defects: a hypothesis with growth hormone
TWI658828B (zh) 用於舒緩及減輕近視之醫藥組合物及其製備方法與用途
CA2884598A1 (en) Contact lens use in the treatment of an ophthalmologic condition
Huxlin et al. Topical rosiglitazone is an effective anti-scarring agent in the cornea
US20230172994A1 (en) Methods of promoting vasculogenesis
CN105555363B (zh) 医药组成物及其用途
JP2023550661A (ja) ドライアイ治療用薬の調製におけるｐ５５ｐｉｋ阻害剤の応用
Sheikpranbabu et al. RETRACTED: Pigment epithelium-derived factor inhibits advanced glycation end-product-induced angiogenesis and stimulates apoptosis in retinal endothelial cells
NZ735959B2 (en) Ophthalmic compositions and methods of use therefor
Loureiro et al. Analysis of different conditioned media secreted by limbal progenitor cells in the modulation of corneal healing
He et al. Impact of Pterygium Excision Combined with Autologous Limbal Stem Cell Transplantation on Microvascular Density, Tear Film Stability, and Corneal Wound Healing
Mudhol et al. The Role of 20% Ethanol in Enhancing Pterygium Surgery Outcomes: A Clinical Study
Elkhawaga et al. Assessment of Corneal Epithelial Healing Rate after Pterygium Excision When Using 2% Hyaluronic Acid.
Ozek et al. Efeito do agente bioprotetor trealose na cicatrização epitelial da córnea após reticulação corneana para ceratocone
CN115721656A (zh) 包含瑞巴派特或其盐的药物组合物及其制备方法和在制备眼用制剂中的用途
김수현 Development of air assisted lamellar keratectomy for corneal haze model and deep anterior lamellar keratoplasty in dogs
Selukar et al. Pterygium excision with conjunctival modified sutureless glueless limbal conjunctival autograft and Mitomycin-C: A prospective clinical study
Xiang et al. Exercise-Induced Irisin Attenuates Trabecular Meshwork Fibrosis and Calcification Via Integrin Αvβ5 Signaling in Glaucoma
HK1219691B (zh) 医药组成物及其用途
HK1209195B (en) Contact lens use in the treatment of an ophthalmologic condition

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: THEIANOVA LIMITED

Free format text: FORMER OWNER(S): AUCKLAND UNISERVICES LIMITED